Traws Pharma FCF/Dettes

Que fait Traws Pharma ? Onconova Therapeutics develops oncology therapeutics targeting specific cellular pathways for cancer treatment. The company focuses on two clinical-stage programs: narazaciclib (ON 123300), a multi-targeted kinase inhibitor for solid tumors and blood cancers, and rigosertib, used alone or with other therapies for solid tumors. Narazaciclib inhibits CDKs, ARK5, and CSF1R at low nM concentrations, while rigosertib is studied in combination with PD-1 inhibitors for K-Ras-driven cancers. The company supports investigator-initiated studies exploring rigosertib's potential in mutated K-Ras cancers. Onconova Therapeutics generates revenue through clinical-stage drug development, with narazaciclib and rigosertib as key products. The company's primary customers are healthcare providers and research institutions conducting clinical trials, particularly those focused on oncology treatments. The target market includes patients with solid tumors and hematological malignancies, as well as researchers investigating K-Ras-driven cancer therapies. The company's business model centers on advancing these therapeutic programs toward regulatory approval and commercialization. Traws Pharma est l'une des entreprises les plus populaires sur Eulerpool.